The company's new CFO made a substantial investment in the company. Should you follow suit?
News & Analysis: BioCryst Pharmaceuticals
BCRX earnings call for the period ending June 30, 2020.
Forget its coronavirus treatment, berotralstat could be BioCryst's next blockbuster drug.
BioCryst’s moonshot probably won’t be as good for shareholders as Moderna’s has already been.
There might be a simple explanation for why the company doubled the expected enrollment in its COVID-19 clinical trial.
An analyst upped his price target for the drugmaker.
Investors are excited about the biotech's potential.
Launching a drug is expensive.
Investors are still hot on the idea that its antiviral drug galidesivir could be used for COVID-19.
BCRX earnings call for the period ending March 31, 2020.